

# MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Laboratory Testing for Prostate Cancer Screening and Management
Policy Number	2.02.48
Category	Technology Assessment
Original Effective Date	08/20/15
Committee Approval Date	12/15/16, 02/15/18, 12/20/18, 12/19/19, 2/18/21, 12/16/21, 12/22/22, 09/21/23
Current Effective Date	01/16/24
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> <li>If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</li> <li>If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit.</li> <li>If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit.</li> <li>If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</li> <li>If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.</li> </ul>

## POLICY STATEMENT

### SCREENING:

- I. New York State Law requires that Health Plan contracts which provide medical coverage that includes coverage for physician's services in a physician's office or provides major medical or similar comprehensive-type coverage shall provide, upon the prescription of a health care provider legally authorized to prescribe under the NYS Education Law, the following coverage for diagnostic screening for prostate cancer.
  - A. Standard diagnostic testing including, but not limited to, a digital rectal exam (DRE) and Prostate-Specific Antigen (PSA) test at any age for individuals having a prior history of prostate cancer; and
  - B. An annual standard diagnostic examination including, but not limited to, a DRE and PSA test for individuals age 50 and over who are asymptomatic and for individuals age 40 and over with a family history of prostate cancer or other prostate cancer risk factors.
- II. Based upon our criteria and lack of the peer-reviewed literature, screening for prostate cancer with prostatic acid phosphatase (PAP) test is considered **not medically necessary** since the sensitivity of the PSA test has been determined to be superior.

### BIOMARKER TESTING FOR PROSTATE CANCER SCREENING:

- III. Based upon our criteria and the lack of peer-reviewed literature, biomarker testing for prostate cancer using other tests have not been proven medically effective and are considered **investigational**. These products include, but are not limited to, the following:
  - A. PROGENSA PCA3 Assay (Prostate Cancer Antigen 3);
  - B. 4Kscore;
  - C. Prostate Health Index (PHI);
  - D. Mitochondrial DNA variant testing (e.g., Prostate Core Mitomics Test);
  - E. ConfirmMDx

# Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT

Policy Number: 2.02.48

Page: 2 of 16

- F. Mi-Prostate Score (MiPS);
- G. TMRSS fusion genes;
- H. PanGIA Prostate;
- I. Apify non-PSA blood test (Armune BioScience);
- J. HOXC6 and DLX1 testing (e.g., SelectMDx); or
- K. PCA3, ERG, and SPDEF RNA expression in exosomes (e.g., ExoDx Prostate IntelliScore, Exosome Diagnostics, MyProstateScore (MPS), and IsoPSA).
- L. Urine-based advanced small noncoding RNA (sncRNA) interrogation (miR Sentinel).

## MANAGEMENT AFTER PROSTATE CANCER DIAGNOSIS:

- IV. Based upon our criteria and assessment of the peer-reviewed literature, gene expression analysis to guide the management of prostate cancer, using the **Oncotype DX Genomic Prostate Score (Oncotype DX Prostate), Prolaris, Decipher Prostate Cancer Classifier (Decipher), or ProMark assay** during initial risk stratification is considered **medically appropriate** in patients who have a prostate and **BOTH** of the following:
  - A. Low- or favorable intermediate-risk disease; AND
  - B. Life expectancy of 10 or more years.
- V. Based upon our criteria and assessment of the peer-reviewed literature, gene expression analysis to guide the management of prostate cancer, using the **Prolaris or Decipher assay** during initial risk stratification, is considered **medically appropriate** in patients who have a prostate and **BOTH** of the following:
  - A. Unfavorable intermediate- and high-risk disease; AND
  - B. Life expectancy of 10 or more years.
- VI. Based upon our criteria and the lack of peer-reviewed literature, **ArteraAI** has not been medically proven to be effective and, therefore, is considered **investigational** for the management of prostate cancer.

## POLICY GUIDELINES

- I. National Comprehensive Cancer Network (NCCN) recommendations for Prostate Cancer Early detection: Risk factors, and interval for repeat testing.

Age/Risk factors	PSA (ng/mL)	Repeat Testing Intervals
45-75 yrs. for those with average risk OR	PSA Less than one (1) AND DRE normal (if done)	2-4 yrs.
40-75 yrs. for individuals with high risk: <ul style="list-style-type: none"><li>• Black/African American individuals</li><li>• Germline mutations that increase the risk for prostate cancer</li><li>• Suspicious family history</li></ul>	Individuals with high risk and PSA less than or equal to 3 ng/ml, DRE normal (if done) <b>AND</b> Individuals with average risk and PSA 1-3 ng/ml, DRE normal (if done)	1-2 yrs.
	PSA greater than 3 AND/OR DRE is very suspicious	Repeat PSA; workup for benign disease; perform multiparametric MRI if available and consider biomarkers that improve the specificity of screening
Greater than 75 yrs. in select patients	PSA less than 4 AND DRE normal (if done) AND no other indications for biopsy	1 to 2 yrs.
If screening continued beyond age 75, perform only with caution in very healthy	PSA Greater than or equal to 4	Same algorithm as individuals ages 40-75 yrs.

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT**

**Policy Number: 2.02.48**

**Page: 3 of 16**

patients with little to no comorbidity, especially if they have never undergone PSA testing or have increasing PSA levels	<b>OR</b> DRE is very suspicious	with PSA greater than three (3) and/or DRE is very suspicious.  Repeat PSA; workup for benign disease; perform multiparametric MRI if available and consider biomarkers that improve the specificity of screening
	Not screened	

II. A tool to estimate life expectancy is the Social Security Administration tables found at: [www.ssa.gov/OACT/STATS/table4c6.html](http://www.ssa.gov/OACT/STATS/table4c6.html)

III. International Society of Urological Pathology (ISUP) Consensus developed a new system that assigned grade groups from 1 to 5, derived from the Gleason score. The lower the Gleason Score, the lower the Gleason grade, this is addressed in NCCN guidelines, risk group chart below:

Risk Group	Stage	Gleason Grade	PSA (ng/ml)	PSA density (ng/ml/g)	Other
Very Low	T1c	1	Less than 10	Less than 0.15	Fewer than three prostate biopsy fragments/cores positive, 50% or less cancer in any fragment/core
Low	T1-T2a	1	Less than 10		
Intermediate - favorable	T2b-T2c	2 or 3	10 to 20		50% or less biopsy cores positive
Intermediate-unfavorable	T2b-T2c	3	10 to 20		50% or more biopsy cores positive
High	T3a	4 or 5	Greater than 20		
Very High	T3b – T4	5			Greater than 4 cores with Grade Group 4 or 5

IV. Patients should be provided with information about the potential benefits and harms of screening and the limits of the current evidence and should be allowed to make their own decision about screening, in consultation with their physician, based upon personal preferences.

V. PSA or DRE individually can detect prostate cancers, however, the most sensitive method for early detection of prostate cancer uses both DRE and PSA. Both tests should be employed in a program of early prostate cancer detection.

VI. The Health Plan and its employees adhere to all State and Federal laws concerning the confidentiality of genetic testing and the results of genetic testing. All records, findings and results of any genetic test performed on any person shall be deemed confidential and shall not be disclosed without the written informed consent of the person to whom such genetic test relates. This information shall not be released to any person or organization not specifically authorized by the individual subject of the test or in compliance with applicable law.

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT**

**Policy Number: 2.02.48**

**Page: 4 of 16**

- VII. Genetic testing is appropriate only when performed by a qualified laboratory certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and offered in a setting with adequately trained health care professionals who are qualified to provide appropriate pre- and post-test counseling.
- VIII. Genetic testing is contract dependent. Coverage only applies to members with a valid contract; coverage is not provided for family members without a valid contract.

**DESCRIPTION**

Prostate cancer is the second most common cancer in the United States with a five-year overall survival of nearly 100% because most prostate cancer diagnosed is a localized disease. Treatment for prostate cancer may include radical prostatectomy, radiation therapy, androgen deprivation therapy, or a combination of any of these treatment options. Research shows that prostate cancer specific mortality is low, with indolent disease often going undiagnosed in patients who die of other causes. Individuals with newly diagnosed prostate cancer can have either aggressive or indolent forms of the disease, and current tools are unable to discriminate between the two. Consequently, all patients are treated as though they have aggressive disease, which leads to overtreatment.

Prostate-Specific Antigen (PSA) is a glycoprotein produced primarily by the epithelial cells that line the acini and ducts of the prostate gland. PSA is concentrated in prostatic tissue, and serum PSA levels are normally low. Disruption of the normal prostatic architecture, such as by prostatic disease, allows for greater amounts of PSA to enter the general circulation. Elevated serum PSA levels have become an important marker of prostate pathologies, which include benign prostatic hypertrophy, prostatitis, and especially prostate cancer. The higher the PSA, the more likely cancer may be present. The PSA cutoff of 4 ng/mL is associated with an appreciable number of false-positive findings, which diminishes the test's predictive value and results in unnecessary biopsies for those with benign conditions. Moreover, the use of this cutoff is associated with a false-negative rate of 20% (i.e., approximately 20% of men with diagnosed prostate cancer have PSA levels below 4 ng/mL). It is most commonly used as an adjunct to DRE. Serum total PSA was the only PSA-based test available in early detection programs for prostate cancer. Since then, several PSA derivatives have been developed and proposed to improve the performance of the PSA measurement, thus possibly increasing specificity and decreasing unnecessary biopsies. Benign prostate conditions produce more free PSA (fPSA), whereas cancer produces more of the complexed PSA (cPSA). The free-to-total PSA ratio (fPSA/tPSA) may be a useful measure to be used as an adjunct to PSA testing. The fPSA and cPSA measurements can be used when levels are between 4 and 10 ng/mL to help decide whether a biopsy is needed.

Prostatic acid phosphatase (PAP) is an isoenzyme whose levels are markedly elevated in invasive cancer of the prostate. The PAP test can be utilized in the diagnosis and staging of patients with prostatic carcinoma and in monitoring and following a patient's response to therapy. However, it is rarely used since the PSA test has been proven to be more sensitive than the PAP test.

Molecular markers are being actively researched and being proposed as a method for risk-stratifying individuals with prostate cancer to make informed decisions related to biopsy/re-biopsy and treatment.

<b>Biomarkers</b>	<b>Molecular Markers</b>
<b>URINE BASED BIOMARKERS</b>	
PCA3 (Progensa)	Prostate cancer antigen 3 (PCA3) is a prostate specific noncoding messenger RNA (mRNA) that has been found to be over expressed in greater than 90% of all prostate tumors compared to that of benign prostatic tissue. The PCA3 Score is intended for use in conjunction with standard-of-care diagnostic algorithms as an aid in the diagnosis of prostate cancer.
SelectMDx	The SelectMDx (MDxHealth, Irvine, CA, USA) assay measures the mRNA levels of two genes, HOXC6 and DLX1, that are known to be overexpressed in aggressive

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT**

Policy Number: 2.02.48

Page: 5 of 16

	prostate cancer. Completed after abnormal PSA and DRE, and gives a risk score to guide surveillance.
ExoDx (Intelliscore)	The ExoDx prostate Intelliscore (Exosome Diagnostics Inc., Cambridge, MA, USA) is a non-DRE urine exosome-based assay that measures PCA3 and ERG (Vets erythroblastosis virus E26 oncogene homologs) RNA levels along with a control gene, SPEDF. It then combines the molecular markers with SOC (standard of care) variables (PSA, race, age, family history) to delineate the risk of detecting > GGG 2 prostate cancer on biopsy. No DRE needed, provides a risk score before biopsy
MiPs	MiPS (University of Michigan, MLabs) is a post-DRE urine assay which is based on multiplex analysis of T2-ERG fusion, PCA3, and serum PSA (KLK3). Completed after abnormal PSA and DRE and gives a risk score.
PanGIA	A multi-analyte urine assay with algorithmic analysis that estimates an individual's risk of having prostate cancer. The test is marketed as a method to determine whether a patient should undergo a biopsy. Completed after abnormal PSA and DRE, guides surveillance.
<b>SERUM BASED BIOMARKERS</b>	
4K	Detection of 4 different kallikrein proteins: total PSA, free PSA, intact PSA, and human kallikrein 2 (hK2). These values are then combined with patient age, DRE results (abnormal or normal), as well as results of prior prostate biopsies to provide a probability score of 0–100% of detecting clinically significant prostate cancer. The 4Kscore test can distinguish men with a low risk of having aggressive prostate cancer on biopsy from those with a high risk.
PHI	Analyzes the levels of free PSA, total PSA and the [-2] form of proPSA (p2PSA). It is calculated by using the following formula: $([-2] \text{ proPSA} / \text{free PSA}) \times \sqrt{\text{PSA}}$ . PHI predicts the likelihood of progression during active surveillance.
<b>TISSUE BASED BIOMARKERS</b>	
Confirm MDx	DNA methylation assay that is prostate tissue biopsy-based. This test evaluates the methylation status of several genes known to be frequently found in prostate cancer: Glutathione S-Transferase Pi 1 (GSTP1), Adenomatous Polyposis Coli (APC), and Ras association domain family member 1 (RASSF1). These markers have been demonstrated to have a “field effect,” meaning a positive ConfirmMDx test in a cancer negative biopsy suggests that occult cancer was missed during the prostate biopsy. Completed after negative biopsy to guide surveillance.

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT****Policy Number: 2.02.48****Page: 6 of 16**

Gene expression and Artificial Intelligence testing for risk assessment for short- and long-term outcomes, and guide in active surveillance decision in low risk and favorable intermediate risk individuals:

<b>Test name</b>	<b>Description</b>	<b>Used to determine</b>
The Oncotype DX prostate test (AKA Genomic Prostate Score Test)	a multigene reverse transcription polymerase chain reaction (RT-PCR) assay designed to analyze underlying tumor biology in tumor tissue from diagnostic formalin-fixed paraffin-embedded (FFPE) core needle biopsies. The test includes five reference genes and 12 cancer genes representing distinct biological pathways with a known role in prostate tumorigenesis.	The Genomic Prostate Score (GPS) is calculated from the reference normalized expression of the 12 cancer-related genes. The GPS score ranges from 0 to 100 with the higher score reflecting a higher risk.
The Prolaris test	a gene expression-based assay that directly measures tumor cell growth characteristics in 31 genes related to cell cycle progression (CCP) and 15 housekeeping genes.	A CCP score is determined which is used to predict 10-year prostate cancer specific disease progression and mortality. CCP scores range from -3.0 to 7.0 with the higher score indicating higher estimated 10-year prostate cancer risk.
The Decipher Prostate RP test	Uses the expression of 2 RNA biomarkers involved in multiple biological pathways across the genome that are associated with aggressive prostate cancer.	Calculates the probability of clinical metastasis within five years of radical prostatectomy surgery.
The Decipher Prostate Biopsy test	a whole transcriptome test, utilizes 22 coding and non-coding biomarkers that span seven cancer pathways.	Determines whether the patient should undergo active surveillance, local therapy alone, or multi-modal therapy.
ProMark	biopsy-based Prostate Cancer prognostic assay that utilizes a multiplex immunofluorescence imaging platform to quantify the values of 8 protein biomarkers demonstrated to be relevant to Prostate Cancer aggressiveness in men with Gleason 3+3 and 3+4 Prostate Cancer.	biomarker values are incorporated into a risk score (ProMark Score; range: 1-100) indicating the likelihood of having high-risk disease.
ArteraAI	An algorithm assesses digital images from the patient's biopsy and learns from the patient's clinical data.	Biomarkers can predict therapeutic benefit and prognosticate long-term outcomes to enable cancer therapy personalization.

**RATIONALE**

The National Comprehensive Cancer Network (NCCN) Guidelines of relevance to this policy:

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT****Policy Number: 2.02.48****Page: 7 of 16**

<b>Guideline</b>	<b>Version</b>	<b>Recommendations</b>
Prostate Cancer Early Detection Guideline	V1.2023	<ul style="list-style-type: none"> <li>• Please see policy Guideline IV.</li> </ul>
Prostate cancer	V1.2023	<ul style="list-style-type: none"> <li>• Decipher- should be considered if not previously performed to inform adjuvant treatment if adverse features are found post-RP.</li> <li>• Patients with NCCN low, favorable intermediate, unfavorable intermediate, or high-risk disease and life expectancy <math>\geq 10</math> y may consider the use of the following tumor-based molecular assays: Decipher, Oncotype DX Prostate, and Prolaris.</li> <li>• ArteraAI Prostate (category 2B) also known as a multi-modal AI biomarker, has trained and validated multiple AI-derived digital histopathology-based biomarkers from five phase III randomized radiation-based trials.</li> </ul>

The American Urological Association (AUA) states:

- Clinicians should offer regular prostate cancer screening every two to four years to people aged 50 to 69 years. (Strong Recommendation; Evidence Level: Grade A)
- When screening for prostate cancer, clinicians should use PSA as the first screening test. (Strong Recommendation; Evidence Level: Grade A)
- For people with a newly elevated PSA, clinicians should repeat the PSA prior to a secondary biomarker, imaging, or biopsy. (Expert Opinion)
- Clinicians should engage in shared decision making with people for whom prostate cancer screening would be appropriate and proceed based on a person's values and preferences. (Clinical Principle)
- Clinicians may begin prostate cancer screening and offer a baseline PSA test to people between ages 45 to 50 years. (Conditional Recommendation; Evidence Level: Grade B)
- Better options are needed to stratify patients and to confirm the type of prostate cancer so that patients with aggressive disease receive treatment, while those with a more indolent disease may be treated more conservatively and may benefit from active surveillance.
- Does not recommend routine screening in individuals between ages 40 to 54 years at average risk. For individuals younger than age 55 years at higher risk, decisions regarding prostate cancer screening should be individualized based upon risk factors.

The U.S. Preventive Services Task Force (USPSTF) updated their guidelines on *Prostate Cancer: Screening (2018)* which states:

- For individuals aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)-based screening for prostate cancer should be an individual one.
- Before deciding whether to be screened, individuals should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision.
- Clinicians should not screen individuals who do not express a preference for screening (Grade C).
- USPSTF recommends against PSA-based screening for prostate cancer in individuals 70 years and older (Grade D).

ASCO guideline for Molecular Biomarkers in Localized Prostate Cancer is as follows:

- In patients with prostate cancer who are most likely to benefit from active surveillance: Commercially available molecular biomarkers (Oncotype Dx Prostate, Prolaris, Decipher, and ProMark) may be offered in situation in which the assay results, when considered with routine clinical factors, is likely to affect management. (Type: Evidence based; Evidence quality: Intermediate; Recommendation: Moderate))

## Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT

Policy Number: 2.02.48

Page: 8 of 16

- To diagnose clinically significant prostate cancer: Commercially available molecular biomarkers (i.e., Oncotype Dx Prostate, Prolaris, Decipher, and ProMark) may be offered in situations in which the assay result, when considered as a whole with routine clinical factors, is likely to affect management. Routine ordering of molecular biomarkers was not recommended (Type: Evidence based; Evidence quality: Intermediate; Recommendation: Moderate)
- To guide the decision for adjuvant or salvage radiation postprostatectomy: The Expert Panel recommends consideration of a commercially available molecular biomarker (e.g., Decipher) may be offered in situations in which the assay result, when considered as a whole with routine clinical factors, is likely to affect management. In the absence of prospective clinical trial data, routine use of genomic biomarkers in the postprostatectomy setting to determine adjuvant versus salvage radiation or to initiate systemic therapies should not be offered (Type: Evidence based; Evidence quality: Intermediate; Strength of recommendation: Moderate).
- Comparative strengths and weaknesses of genomics or MRI in identifying clinically significant prostate cancer: In patients with newly diagnosed prostate cancer who are eligible for active surveillance, both MRI and genomics are intended to identify clinically significant cancers. Their use is endorsed only in situations in which the result, when considered with routine clinical factors, is likely to affect management. This may include, for instance, the initial management of patients who are potentially eligible for active surveillance, where each of these approaches may provide clinically relevant and actionable information. These tests may provide information independent of routine clinical parameters and independent of one another (Type: Informal consensus; benefits/harms ratio unknown; Evidence quality: Low; Strength of recommendation: Weak).

Egger et al. (2019), as part of an American Society of Clinical Oncology (ASCO) Multidisciplinary Expert Panel, conducted a systematic literature review of localized prostate cancer biomarker studies between Jan 2013 and 2019. Guidelines with recommendations for available tissue-based prostate cancer biomarkers were developed with a focus on patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant or salvage radiation therapy (RT), and the value of tissue biomarkers compared to magnetic resonance imaging (MRI). Numerous molecular biomarkers have been developed to improve risk stratification and patient management. Few panels have undergone extensive validation; however, five are commercially available and have been shown in retrospective analyses to provide additional information beyond standard clinical models in prognostication or patient selection for therapy. The authors indicated that, while these tissue-based tests may improve risk stratification when added to standard clinical parameters, their use may be offered in situations in which the assay result, when considered as a whole with routine clinical factors, is likely to affect management. Examples included select patients with high-volume low-risk or favorable intermediate-risk prostate cancer considering active surveillance, and patients with high-risk features for treatment intensification. The authors also noted that, while testing may influence management decisions, there is no high-level evidence to indicate that the results from these panels improve quality of life or cancer-specific outcomes. There have been additional biomarkers evaluated that do not have sufficient data to be clinically actionable or that are not commercially available. Continued investigation of tissue-based molecular biomarkers in the context of clinical trials was recommended.

Analytical validity of the Oncotype DX Prostate assay was reported by Knezevic et al. (2013). The research showed that the assay could accurately measure expression of the 12 cancer-related and five reference genes over a range of absolute RNA inputs (0.005-320 ng) with a detection limit of 0.05 ng/ml. The analytic accuracy showed average variation of less than 9.7% across all samples at RNA inputs typical of needle biopsy specimens. The amplification efficiency for the 17 genes in the test ranged from 88% to 100%, with a median of 93% (SD=6%) for all 17 genes in the assay. Analytic precision was assessed by examining variability between replicate results obtained using the same messenger RNA level of 5 ng mRNA was used to reflect the lowest 2.5 percentile of a tumor sample of 0.023 cm<sup>3</sup>. When converted to GPS units (unit measure for reporting test results), the standard deviation for analytic precision was 1.86 GPS units (95% confidence interval [CI], 1.60 to 2.20) on the 100-unit scale. The standard deviation for reproducibility was 2.11 GPS units (95% CI, 1.83 to 2.50) on the 100-point scale.

The evidence for the Decipher assay in patients who have high-risk prostate cancer after radical prostatectomy includes one study of analytic validity; eight studies using archived samples; seven prospective-retrospective designs; one case-control) examining clinical validity; six decision curve analyses examining indirect evidence for clinical utility; and one prospective decision impact study. Relevant outcomes included overall survival, disease-specific survival, test accuracy, test validity, quality of life, and treatment-related morbidity. The clinical validity of the Decipher assay has been



## **Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT**

**Policy Number: 2.02.48**

**Page: 9 of 16**

evaluated in samples of patients with high-risk prostate cancer who are undergoing different interventions following radical prostatectomy. Studies reported some incremental improvement in discrimination. However, it is unclear whether there is consistent improved reclassification—particularly to higher risk categories—or whether the test could be used to predict which patients will benefit from radiotherapy.

A number of different manufacturers make PSA test kits. The FDA approved the PSA test for use with the DRE to help detect prostate cancer in individuals age 50 or older and to monitor patients with a history of prostate cancer. The FDA indications for use of fPSA state the test is used along with a DRE and tPSA for individuals age 50 years or older who have a PSA level between 4–10 ng/mL and a prostate gland that appears of normal size and texture.

Screening for prostate cancer in asymptomatic men can detect tumors at a more favorable stage (disease confined to the prostate), which is theorized to improve survival. Mortality from prostate cancer has decreased, but it has not been established that this event has resulted directly from screening. Because screening may be detecting cancers that would never have caused morbidity or mortality in the host, the value of early detection remains unclear.

Randomized screening trials are in progress both in the USA and Europe to address the relationship between screening and prostate mortality. The specificity of PSA testing is 60% to 70 % when the PSA level is greater than 4.0ng/ml. The evidence from studies that allow a direct comparison of the yields of PSA and DRE suggests that combining both of these tests improve the overall rate of prostate cancer detection when compared to either test alone.

The Prostate, Lung, Colon, and Ovarian Cancer Screening trial (PLCO) randomized 76,685 individuals aged 55 to 74 years at 10 U.S. study centers to annual screening (annual PSA for six years and DRE for four years) or usual care. After 13 years of follow-up, the incidence rate ratio for the screening arm compared to control was 1.12 (95% CI, 1.07-1.17). The investigators did not find a statistically significant difference between the disease-specific mortality rates of the screening group and of the control (RR, 1.09; 95% CI, 0.87-1.36). Despite the impressive sample size, this trial is flawed by prescreening and the high contamination rate of 40% to 52% each year in the control group (i.e., 74% of individuals in the usual care arm were screened at least once). The estimated mean number of screening PSAs (DREs) in the control arm was 2.7 (1.1); this compared to 5.0 (3.5) in the screened arm. In addition, the biopsy rate for those with elevated serum PSA values was relatively low compared to the European trials. The PLCO trial really compared fixed screening versus “opportunistic” screening, and therefore, did not really test the hypothesis that screening with PSA is of value. However, it did show that yearly screening may be of limited value compared to less frequent testing.

In many of the studies evaluating the utility of additional PSA derivatives, the most useful parameters appeared to be fPSA/tPSA and its derivative, %fPSA, which is calculated as the ratio of fPSA to tPSA, expressed as a percentage. Many of the investigators preferred using %fPSA, which is more easily expressed. The studies found that %fPSA, or fPSA/tPSA, was better at discriminating benign from malignant prostatic disease compared to tPSA alone or the other PSA parameters and did not decrease sensitivity to detect cancer, while improving specificity by decreasing the number of unnecessary or negative biopsies.

A large number of studies evaluated cPSA and/or cPSA-associated parameters, such as the ratio of cPSA to tPSA, or cPSA/tPSA. A specific assay for cPSA has been developed. Prior to its development, cPSA was derived by subtracting fPSA from tPSA.

Esteva et al. (2022) demonstrated prostate cancer therapy personalization by predicting long-term, clinically relevant outcomes using a multimodal deep learning architecture and train models using clinical data and digital histopathology from prostate biopsies. They trained and validated models using five phase III randomized trials conducted across hundreds of clinical centers. Histopathological data was available for 5,654 of 7,764 randomized patients (71%) with a median follow-up of 11.4 years. Compared to the most common risk-stratification tool—risk groups developed by the National Cancer Center Network (NCCN)—their models have superior discriminatory performance across all endpoints, ranging from 9.2% to 14.6% relative improvement in a held-out validation set. This artificial intelligence-based tool improves prognostication over standard tools and allows oncologists to computationally predict the likeliest outcomes of specific patients to determine optimal treatment. Outfitted with digital scanners and internet access, any clinic could offer such capabilities, enabling global access to therapy personalization. Although NCCN considers ArteraAI a category 2B recommendation, currently the literature is limited.

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT****Policy Number: 2.02.48****Page: 10 of 16****CODES**

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/appropriate = (NMN).

**CPT Codes**

<b>Code</b>	<b>Description</b>
81313 (E/I)	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (e.g., prostate cancer)
81539 (E/I)	Oncology (high-grade prostate cancer), biochemical assay of four proteins (total PSA, free PSA, intact PSA, and human Kallikrein-s[HK-2]), utilizing plasma or serum prognostic algorithm reported as a probability score (e.g., 4K Score)
81541	Oncology (prostate), mRNA gene expression profiling by real-time RT-PCR of 46 genes (31 content and 15 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a disease-specific mortality risk score (Prolaris® Assay)
81542	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score (Decipher Prostate Cancer Assay)
81551(E/I)	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy (Confirm MDx, MDx Health)
84152	Prostate specific antigen (PSA); complexed (direct measurement)
84153	Prostate specific antigen (PSA); total
84154	Prostate specific antigen (PSA); free
84066 (NMN)	Phosphatase, acid; prostatic (PAP)
81479 (E/I)	Unlisted molecular pathology procedure
0005U (E/I)	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score (ExosomeDx® Prostate (IntelliScore), Exosome Diagnostics, Inc)
0021U (E/I)	Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropporon, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score (Apifyny, Armune BioScience, Inc)
0047U	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score (Oncotype Dx Prostate Cancer Assay)
0113U (E/I)	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score (MyProstateScore, Lynx DX)

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT****Policy Number: 2.02.48****Page: 11 of 16**

<b>Code</b>	<b>Description</b>
0228U (E/I)	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer (PanGIA Prostate, Genetics Institute of America, Entopsis, LLC).
0339U (E/I)	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer. (SelectMDx for Prostate Cancer, MDxHealth, Inc)
0343U (E/I)	Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer. (miR Sentinel Prostate Cancer Test, miR Scientific, LLC)
0359U (E/I)	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer (IsoPSA, Cleveland Diagnostics) ( <i>effective date 01/01/2023</i> )
0376U (E/I)	Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate (ArteraAI Prostate Test, Artera Inc) ( <i>effective 04/01/2023</i> )
0403U (E/I)	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer. (MyProstateScore 2.0, LynxDx)( <i>effective 10/01/2023</i> )
0424U (E/I)	Oncology (prostate), exosome-based analysis of 53 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer (miR Sentinel Prostate Test, miR Scientific LLC) ( <i>effective 01/01/2024</i> )
0433U (E/I)	Oncology (prostate), 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer (Episwitch Prostate Screening Test, Oxford BioDynamics Inc.) ( <i>effective 01/01/2024</i> )

Copyright © 2023 American Medical Association, Chicago, IL

**HCPCS Codes**

<b>Code</b>	<b>Description</b>
G0102	Prostate cancer screening; digital rectal exam
G0103	Prostate cancer screening; prostate specific antigen test (PSA)

**ICD10 Codes**

<b>Code</b>	<b>Description</b>
C61	Malignant neoplasm of prostate
D07.5	Carcinoma in situ of prostate
D29.1	Benign neoplasm of prostate

## Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT

Policy Number: 2.02.48

Page: 12 of 16

Code	Description
D40.0	Neoplasm of uncertain behavior of prostate
N42.30	Unspecified dysplasia of prostate
N42.31	Prostatic intraepithelial neoplasm
N42.32	Atypical small acinar proliferation of prostate
N42.39	Other dysplasia of prostate
R97.20	Elevated prostate specific antigen (PSA)
R97.21	Rising PSA following treatment for malignant neoplasm of prostate
Z12.5	Encounter for screening for malignant neoplasm of prostate
Z85.46	Personal history of malignant neoplasm of prostate

### REFERENCES

- Alford AV, et al. The use of biomarkers in prostate cancer screening and treatment. Rev Urol 2017;19(4):221-234.
- \*American College of Preventive Medicine. Practice policy statement. Screening for prostate cancer in American men. Am J Prev Med 1998;15(1):81-4.
- \*American Urological Association. Prostate-specific-antigen (PSA) best practice policy. Oncol 2000 Feb;14(2).
- \*Auprich M., et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol 2011 Nov;60(5):1045-54.
- \*Auvinen A, et al. Test sensitivity of prostate-specific antigen in the Finnish randomised prostate cancer screening trial. Int J Cancer 2004 Oct 10;111(6):940-3.
- \*Barry MJ. Prostate-specific-antigen testing for early diagnosis of prostate cancer. NEJM 2001 May 3;344(18):1373-7.
- Bellei E, et al. Research of Prostate Cancer Urinary Diagnostic Biomarkers by Proteomics: The Noteworthy Influence of Inflammation. Diagnostics (Basel) 2023 Apr 1;13(7):1318.
- Brooks MA, et al. GPS assay association with long-term cancer outcomes: twenty-year risk of distant metastasis and prostate cancer-specific mortality. JCO Precision Oncol 2021 Feb;5:442-449
- Canfield S, et al. Active surveillance use among a low-risk prostate cancer population in a large US payer system: 17-gene genomic prostate score versus other risk stratification methods. Rev Urol 2017;19(4):203-212.
- \*Chou R, et al. Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:762-71.
- \*Choudhury AD, et al. The role of genetic markers in the management of prostate cancer. Eur Urol 2012 Oct;62(4):577-87.
- \*Crawford ED, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012 Nov;188(5):1726-31.
- Cucchiara V, et al. Genomic markers in prostate cancer decision making. Eur Urol 2018 Apr;73(4):572-582.
- Darst BF, et al. The four-kallikrein panel is effective in identifying aggressive prostate cancer in a multiethnic population. Cancer Epidemiol Biomarkers Prev 2020 May 8.
- De la Calle CM, et al. Clinical utility of 4Kscore, ExosomeDx and magnetic resonance imaging for the early detection of high grade prostate cancer. The Journal of Urology 2021 Feb;205:452-460.
- Del Pino-Sedeño T, et al. Molecular Biomarkers for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Open Sci 2022 Nov 10;46:105-127.

**Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT**

**Policy Number: 2.02.48**

**Page: 13 of 16**

Dess RT and Spratt DE. Why the UK should consider gene expression testing in prostate cancer. Clin Oncol (R Coll Radiol) 2020 Mar;32(3):149-155.

\*Durand X, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012 Jul;110(1):43-9.

\*Eggener SE, et al. Molecular biomarkers in localized prostate cancer: ASCO Guideline. J Clin Oncol 2020 May a;38(13):1274-1494.

Esteva A, et al. Prostate cancer therapy personalization via multi-modal deep learning on randomized phase III clinical trials. NPJ Digit Med 2022 Jun 8;5(1):71.

Eure G, et al. Use of a 17-gene prognostic assay in contemporary urologic practice: results of interim analysis in an observational cohort. Urology 2017 Sep;107:67-75.

Fine ND, et al. Genomic classifiers for treatment selection in newly diagnosed prostate cancer. BJU Int 2019 May 4 [Epub ahead of print].

\*Gittelman M., et al. PROGENSA®PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study. J Urol 2013 Jul;190(1):64-9.

\*Ilic D, et al. Screening for prostate cancer. cochrane database of systematic reviews 2006, Issue 3. Art. No.: CD004720.

Karnes RJ, et al. Validation of a genomic risk classifier to predict prostate cancer-specific mortality in men with adverse pathological features. Eur Urol 2018 Feb;73(2):168-175.

Kearns JT, et al. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening. Cancer 2018.

\*Knezevic D, et al. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 2013;14:690.

Kohaar I, et al. A rich array of prostate cancer molecular biomarkers: opportunities and challenges. Int J Mol Sci 2019 20(8), 1813.

Lamy PJ, et al. Prognostic biomarkers used for localized prostate cancer management: a systematic review. Eur Urol Focus 2018 Dec;4(6):790-803.

Leapman MS, et al. Association between a 17-gene genomic prostate score and multiparametric prostate MRI in men with low and intermediate risk prostate cancer (PCa). PLoS One 2017 Oct 10;12(10):e0185535.

Lin DW, et al. 17-gene genomic prostate score test results in the Canary Prostate Active Surveillance Study (PASS) cohort. J Clin Oncol 2020 May 10;38(14):1549-1557.

\*Lin DW, et al. Urinary TMPRSS2: ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res 2013 May 1;19(9):2442-2450.

Loeb S and Ross AE. Genomic testing for localized prostate cancer: where do we go from here? Curr Opinion Urol 2017 Sep;27(5):495-499.

Martin DT, et al. Prostate cancer genomic classifier relates more strongly to Gleason grade group than prostate imaging reporting and data system score in multiparametric prostate magnetic resonance imaging-ultrasound fusion targeted biopsies. Am J Roent 2019 Jun;212(6):1244-1252.

\*Merola R, et al. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J Exp Clin Cancer Res 2014 Feb 6;34(1):15.

Na R, et al. Clinically available RNA profiling tests of prostate tumors: utility and comparison. Asian J Androl 2016 Jul-Aug;18(4):575-9.

Narayan VM. A critical appraisal of biomarkers in prostate cancer. World J Urol 2020 Mar;38(3):547-554.

## Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT

Policy Number: 2.02.48

Page: 14 of 16

\*National Cancer Institute (NCI) Cancer Information Service (CIS). Cancer facts. Questions and answers about the prostate-specific antigen (PSA) test. Reviewed 2021 Feb 24.  
[<http://www.cancer.gov/cancertopics/factsheet/Detection/PSA>] accessed 06/15/23.

\*National Cancer Institute (NCI). PDQ® Cancer Information Summary. Prostate Cancer (PDQ®): Treatment: Health Professional. 2005b. Bethesda (MD): National Cancer Institute. Updated 2021 Mar 18.  
[<http://www.cancer.gov/cancertopics/pdq/screening/prostate/healthprofessional>] accessed 06/15/23.

\*National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology. Prostate Cancer. V.4.2022.  
[[https://www.nccn.org/professionals/physician\\_gls/pdf/prostate\\_blocks.pdf](https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf)] accessed 06/15/23.

\*National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Prostate cancer early detection. Version 1.2023 [[http://www.nccn.org/professionals/physician\\_gls/pdf/prostate\\_detection.pdf](http://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf)] accessed 06/15/23.

New York State Consolidated Insurance Law. Article 32 § 3216 (i)(11-a).

Nguyen PL, et al. Ability of a genomic classifier to predict metastasis and prostate cancer-specific mortality after radiation or surgery based on needle biopsy specimens. *Eur Urol* 2017 Nov;72(5):845-852.

Olleik G, et al. Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. *J Natl Compr Canc Netw* 2018 Nov;16(11):1340-1351.

Osses D, et al. Prediction medicine: biomarkers, risk calculators and magnetic resonance imaging as risk stratification tools in prostate cancer diagnosis. *Int J Mol Sci* 2019 20(7), 1637.

Saltman A, et al. Prostate cancer biomarkers and multiparametric MRI: is there a role for both in prostate cancer management? *Ther Adv Urol* 2021 13:1-11.

Rayford W, et al. Improving risk stratification in a community-based African American population using cell cycle progression score. *Transl Androl Urol* 2018;7(Supp 4):S384-S391.

Salmasi A, et al. A 17-gene genomic prostate score assay provides independent information on adverse pathology in the setting of combined multiparametric magnetic resonance imaging fusion targeted and systematic prostate biopsy. *J Urol* 2018; 200: 564-572.

Schwen ZR, et al. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance: PHI+mpMRI to predict grade reclassification in AS. *BJU Int* 2020 126(3), 373–378.

Shore ND, et al. A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population—The MiCheck-01 prospective trial. *Urol Oncol* 2020 Aug;38(8):683.e1-683.e10.

Tan GH, et al. Smarter screening for prostate cancer. *World J Urol* 2019 37(6), 991–999.

Tinay I, et al. Functional roles and potential clinical application of miRNA-345-5p in prostate cancer. *Prostate* 2018 Sep;78(12):927-937.

\*Thompson IM, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. *NEJM* 2004 May 27;350(22):2239-46. Erratum: *NEJM* 2004 Sep 30;351(14):1470.

Tidd-Johnson A, et al. Prostate cancer screening: Continued controversies and novel biomarker advancements. *Curr Urol* 2022 Dec;16(4):197-206.

\*Urological Sciences Research Foundation. PCA3: A Genetic Marker of Prostate Cancer. Aug 2003; updated 2007.  
[<http://www.usrf.org/news/PCA3/PCA3.html>] accessed 06/15/23.

US Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force Recommendation Statement Prostate Cancer Screening. 2018 May 8.  
[<https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening>] accessed 06/15/23.

\*US Preventive Services Task Force Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. 2008 Aug 5;149(3):185-91.

## **Medical Policy: LABORATORY TESTING FOR PROSTATE CANCER SCREENING AND MANAGEMENT**

**Policy Number: 2.02.48**

**Page: 15 of 16**

Van Leenders GJLH, et al ISUP Grading Workshop Panel Members. The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. Am J Surg Pathol 2020 Aug;44(8):e87-e99.

Vertosick EA, et al. Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. J Urol 2020 204(2), 281–288.

Wei JT, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol 2023 Jul;210:46-53.

Wei JT, et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol 2023 Jul;210:54-63.

Zhang G, et al. Assessment on clinical value of prostate health index in the diagnosis of prostate cancer. Cancer Med 2019 Sep; 8(11): 5089–5096.

\*Key Article

### **KEY WORDS**

EGIR, Prostate-specific antigen, Prostatic acid phosphatase, PAP, PSA, PCA3Plus, PCA3 gene, 4KScore, Prostate Health Index, ConfirmMDx, Prolaris<sup>®</sup>, Oncotype DX<sup>®</sup> Prostate, Confirm MDX<sup>®</sup>, Gene expression analysis for the prostate, ArteraAI.

### **CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently a National Coverage Determination (NCD) for Prostate Cancer Screening Tests (210.1). Please refer to the following NCD website for Medicare Members:

<http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=268&ncdver=2&bc=AgAAgAAAAAAA&> accessed 08/30/23.

There is currently a National Coverage Determination (NCD) for Prostate Specific Antigen (PSA) (190.31). Please refer to the following websites for Medicare Members: <http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=152&ncdver=1&bc=AgAAgAAAAAAA&> accessed 08/30/23.

There is currently a Local Coverage Determination (LCD) for Molecular Pathology Procedures which includes PCA3 (L3500). Please refer to the following LCD website for Medicare Members:

[https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35000&ver=138&CntrctrSelected=298\\*1&Cntrctr=298&s=41&DocType=1&bc=AAgAAQAQgAAA&=](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35000&ver=138&CntrctrSelected=298*1&Cntrctr=298&s=41&DocType=1&bc=AAgAAQAQgAAA&=) accessed 08/30/23.

There is currently a Local Coverage Determination (LCD) for Biomarker Testing (Prior to Initial Biopsy) for Prostate Cancer Diagnosis (L37733). Please refer to the following LCD website for Medicare Members:

[https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37733&ver=22&CntrctrSelected=298\\*1&Cntrctr=298&s=41&DocType=1&bc=AAgAAQAQgAAA&=](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=37733&ver=22&CntrctrSelected=298*1&Cntrctr=298&s=41&DocType=1&bc=AAgAAQAQgAAA&=) accessed 08/30/23.

There is currently a no National Coverage Determination (NCD) or Local Coverage Determination (LCD) for gene expression analysis for prostate cancer management.

There is currently a Local Coverage Determination (LCD) for MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease (L38339). Please refer to the following LCD website for Medicare members:

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=38339> accessed 08/30/23.

There is currently a Local Coverage Determination (LCD) for Molecular Pathology Procedures (L35000). Please refer to the following LCD website for Medicare members:

[https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35000&ver=138&CntrctrSelected=298\\*1&Cntrctr=298&s=41&DocType=Active&bc=AggAAAIgAAA&=](https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35000&ver=138&CntrctrSelected=298*1&Cntrctr=298&s=41&DocType=Active&bc=AggAAAIgAAA&=) accessed 08/30/23.

